Basket | Login


Collaboration with other Alzheimer’s disease reasearch projects

Who are the PharmaCog partners?

To ensure the potential of PharmaCog to patients is maximised, PharmaCog partners will work closely with investigators in other major Alzheimer Initiatives across Europe and the USA. In particular, PharmaCog's WP5 will interact closely with:

ADNI: A major goal of the study has been to establish and validate markers the predict the progression of Alzheimer’s disease. Data collected throughout this study are available to the research community.

Link :

Coalition against major diseases: A new database of more than 4,000 Alzheimer’s disease patients who have participated in 11 industry-sponsored clinical trials made available to qualified researchers around the world. This will enable researchers to more accurately predict the true course of Alzheimer’s disease, thereby enabling the design of more efficient clinical trials. Patient identifiers will not be included in the database, thereby ensuring patient privacy.

Link :



Last Updated: Monday 12 November 2012


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations